FENG Yuting, LIU Zhihan, CHAI Qianyun, LUO Minjing, GAO Yicheng, TAO Liyuan, FEI Yutong. Control of Confounders and Covariates in Real-World Studies: Cerebrovascular Diseasebased Cases Explanation[J]. Chinese Journal of Stroke, 2022, 17(12): 1304-1309.
[1]康德英. 浅议真实世界研究[J]. 中国癌症防治杂志,2017,9(2):100-103.
[2]SCHWARTZ D,LELLOUCH J. Explanatory and pragmatic attitudes in therapeutical trials[J]. J Clin Epidemiol,2009,62(5):499-505.
[3]梁立荣. 真实世界研究的是与非[J]. 中华结核和呼吸杂志,2018,41(5):323-326.
[4]孙鑫,谭婧,唐立,等. 重新认识真实世界研究[J]. 中国循证医学杂志,2017,17(2):126-130.
[5]金鑫瑶,郑文科,张俊华,等. 推进真实世界研究的透明化[J]. 世界中医药,2019,14(12):3106-3110.
[6]史彤. 真实世界研究用于医疗器械研发现状及展望[J]. 现代工业经济和信息化,2022,12(8):190-191,197.
[7]中国临床医学真实世界研究施行规范专家委员会. 中国临床医学真实世界研究施行规范[J]. 解放军医学杂志,2018,43(1):1-6.
[8]国家药品监督管理局. 真实世界证据支持药物研发与审评的指导原则(试行)[EB/OL].(2020-01-03)[2022-10-10]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200107151901190.html.
[9]胡斌,马巧琳,杨帆,等. 基于真实世界研究方法的医学研究进展[J]. 中医临床研究,2022,14(22):141-145.
[10]崔鑫,韩晟,刘峘,等. 基于一项前瞻性真实世界队列研究的芪龙胶囊治疗缺血性脑卒中的成本-效果分析[J]. 中国中药杂志,2022,47(11):3111-3117.
[11]李峥,刘宇. 混杂偏倚的控制——分层分析与多因素分析[J]. 中国护理管理,2021,21(2):279.
[12]VAN ALEBEEK M E,ARNTZ R M,EKKER M S,et al. Risk factors and mechanisms of stroke in young adults:the FUTURE study[J]. J Cereb Blood Flow Metab,2018,38(9):1631-1641.
[13]李新,关明云. 医学实验研究中混杂因素的控制[J]. 辽宁中医药大学学报,2010,12(7):194-195.
[14]LIN H F,HUANG L C,CHEN C H,et al. Age and sex differences in the effect of parental stroke on the progression of carotid intima-media thickness[J]. Atherosclerosis,2015,241(1):229-233.
[15]LUO Y,JIN H,GUO Z N,et al. Effect of hyperhomocysteinemia on clinical outcome and hemorrhagic transformation after thrombolysis in ischemic stroke patients[J/OL]. Front Neurol,2019,10:592[2022-10-10]. https://doi.org/10.3389/fneur.2019.00592.
[16]WELTEN S J G C,ONLAND-MORET N C,BOER J M A,et al. Age at menopause and risk of ischemic and hemorrhagic stroke[J]. Stroke,2021,52(8):2583-2591.
[17]胡红林. 倾向评分法在医学研究中的应用和分析[D]. 武汉:华中科技大学,2009.
[18]HAJIAN TILAKI K. Methodological issues of confounding in analytical epidemiologic studies[J]. Caspian J Intern Med,2012,3(3):488-495.
[19]NTAIOS G,MICHEL P,GEORGIOPOULOS G,et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke:the global COVID-19 stroke registry[J/OL]. Stroke,2020,51(9):e254-e258[2022-10-10]. https://doi.org/10.1161/strokeaha.120.031208.
[20]赵厚宇,詹思延. 疾病风险评分在药物流行病学研究中的应用[J]. 中华流行病学杂志,2017,38(2):261-266.
[21]黄丽红,魏永越,陈峰. 如何控制观察性疗效比较研究中的混杂因素:(一)已测量混杂因素的统计学分析方法[J]. 中华流行病学杂志,2019,40(10):1304-1309.
[22]WYSS R,ELLIS A R,BROOKHART M A,et al. Matching on the disease risk score in comparative effectiveness research of new treatments[J]. Pharmacoepidemiol Drug Saf,2015,24(9):951-961.
[23]NOORDZIJ M,LEFFONDRÉ K,VAN STRALEN K J,et al. When do we need competing risks methods for survival analysis in nephrology?[J]. Nephrol Dial Transplan,2013,28(11):2670-2777.
[24]ZHANG Y,YANG H,LI S,et al. Consumption of coffee and tea and risk of developing stroke,dementia,and poststroke dementia:a cohort study in the UK Biobank[J/OL]. PLoS,2021,18(11):e1003830[2022-10-10]. https://doi.org/10.1371/journal.pmed.1003830.
[25]CHEN Y,BRIESACHER B A. Use of instrumental variable in prescription drug research with observational data:a systematic review[J]. J Clin Epidemiol,2011,64(6):687-700.
[26]LARSSON S C,SCOTT R A,TRAYLOR M,et al. Type 2 diabetes,glucose,insulin,BMI,and ischemic stroke subtypes:mendelian randomization study[J]. Neurology,2017,89(5):454-460.
[27]JAGER K J,ZOCCALI C,MACLEOD A,et al. Confounding:what it is and how to deal with it[J]. Kidney Int,2008,73(3):256-260.
[28]VAN STRALEN K J,DEKKER F W,ZOCCALI C,et al. Confounding[J/OL]. Nephron Clin Pract,2010,116(2):c143-147[2022-10-10]. https://doi.org/10.1159/000315883.
Medical Quality Management and Promotion Branch of Chinese Stroke Association, Writing Group of Chinese Expert Consensus on Standardized Bilingual Terminology for Atherosclerotic Cerebrovascular Disease.